PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Novartis Files Tafinlar-Mekinist Combo for NSCLC
December 6, 2016
- Daiichi Sankyo’s HER2-Targeting ADC Gets Fast-Track Status in US
December 5, 2016
- Takeda, Lightstone Ventures Set Up Neuroscience R&D Firm
December 5, 2016
- Shionogi’s Sakigake-Designated Flu Drug Delivers Add’l Favorable PII Data
December 5, 2016
- Annual Price Revision Could Plunge Pharma Industry into Doldrums: Pfizer Japan Chief
December 5, 2016
- FDA Accepts sNDA for Abilify Maintena’s Bipolar I Disorder Indication
December 2, 2016
- Novartis Seeks Aplastic Anemia Indication for Revolade, Neoral
December 2, 2016
- Takeda to Build Dengue Vaccine Plant in Germany
December 2, 2016
- JACE for Giant Congenital Melanocytic Nevus Covered by Health Insurance: J-TEC
December 2, 2016
- Pfizer Japan Completes Transfer of Generics from Hospira Japan
December 2, 2016
- Oncolys Licenses Oncolytic Virus Telomelysin to Hengrui in China
December 2, 2016
- Shionogi Files Abuse-Deterrent Painkiller Oxycodone in Japan
December 1, 2016
- Chugai Seeks Large Vessel Vasculitis Indication for Actemra
December 1, 2016
- Signs of Growth in Prescribing SGLT-2 Inhibitors with Favorable Environment Change
November 30, 2016
- Shionogi Says UK Court Finds Its HIV Drug Patent Invalid, Set to Challenge Ruling
November 29, 2016
- Santen Eyes US Filing for Opsiria Early Next Year
November 29, 2016
- Chugai Licenses Class I PI3K Inhibitor to German Drug Maker
November 29, 2016
- Ono to Offer New Invoice Prices for Opdivo Early on to Avoid Distribution Confusion
November 29, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Drug Makers Concerned about Cost-Effective Assessments Used for NHI Price Cuts: Survey
November 28, 2016
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…